Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

141. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis

Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

142. Cohort study: Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events

Cohort study: Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events Article Text Prognosis Cohort study Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events David N Juurlink Statistics from Altmetric.com Commentary on: Charlot M , Grove EL , Hansen PR , et al . Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time

2012 Evidence-Based Medicine

143. Randomised controlled trial: Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors

Randomised controlled trial: Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you (...) Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors Article Text Therapeutics Randomised controlled trial Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors George Triadafilopoulos Statistics from Altmetric.com Commentary on: Galmiche JP , Hatlebakk J , Attwood

2012 Evidence-Based Medicine

144. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease (Abstract)

Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease Unexplained chest pain is potentially attributable to gastro-oesophageal reflux disease (GORD) or oesophageal motility disorders. Reflux chest pain may occur without heartburn. We explored the response of unexplained chest pain to proton pump inhibitor (PPI) therapy in randomised clinical trials (RCTs), differentiating patients

2012 EvidenceUpdates

145. Celecoxib versus Non-COX-2 Selective Non-steroidal Anti-inflammatory Drugs and Proton Pump Inhibitors: A Review of the Clinical Effectiveness, Safety, and Cost Effectiveness

Celecoxib versus Non-COX-2 Selective Non-steroidal Anti-inflammatory Drugs and Proton Pump Inhibitors: A Review of the Clinical Effectiveness, Safety, and Cost Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence (...) be copied and used for non-commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Celecoxib versus Non-selective Non-steroidal Anti-Inflammatory Drugs and Proton Pump Inhibitors: Clinical Effectiveness, Safety, and Cost-Effectiveness

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

146. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel

A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

147. Proton pump inhibitors in long-term use: reports of hypomagnesaemia

Proton pump inhibitors in long-term use: reports of hypomagnesaemia Proton pump inhibitors in long-term use: reports of hypomagnesaemia - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Proton pump inhibitors in long-term use: reports of hypomagnesaemia Healthcare professionals should consider measuring magnesium levels before starting PPI treatment and repeat measurements periodically during prolonged treatment. Published 11 December 2014 From: Therapeutic area: Contents Article (...) date: April 2012 Proton pump inhibitors (PPIs) are a class of drugs for the treatment of duodenal and gastric ulcers, and are used in combination with antibacterials for the eradication of Helicobacter pylori. They are also used to treat gastroesophageal reflux disease, dyspepsia, and Zolligner-Ellison syndrome and for prevention and treatment of ulcers associated with the use of non-steroidal anti-inflammatory drugs. The class of PPIs includes esomeprazole (Nexium), lansoprazole (Zoton

2012 MHRA Drug Safety Update

148. Proton pump inhibitors in long-term use: increased risk of fracture

Proton pump inhibitors in long-term use: increased risk of fracture Proton pump inhibitors in long-term use: increased risk of fracture - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Proton pump inhibitors in long-term use: increased risk of fracture Recent epidemiological evidence of an increased risk of fracture with long-term use of proton pump inhibitors (PPIs). Published 11 December 2014 From: Therapeutic area: Contents Article date: April 2012 Observational studies

2012 MHRA Drug Safety Update

149. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Full Text available with Trip Pro

Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Saini SD, Fendrick AM, Scheiman JM Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of proton-pump inhibitor (PPI) co-therapy to reduce dyspepsia in patients aged 50 years or older, receiving long-term, low-dose aspirin, for the secondary prevention of cardiovascular disease

2011 NHS Economic Evaluation Database.

150. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis

Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

151. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial Full Text available with Trip Pro

A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial o evaluate the efficacy and tolerability of add-on treatment with lesogaberan (AZD3355), a novel reflux inhibitor, in patients with persistent gastro-oesophageal reflux disease (GORD) symptoms despite proton pump inhibitor (PPI) therapy.double-blind, placebo-controlled, randomised, parallel-group

2011 EvidenceUpdates Controlled trial quality: predicted high

152. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies (Abstract)

Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies Proton pump inhibitors (PPIs) are widely used in several acid-related gastrointestinal disorders. In vivo studies have suggested that gastric suppression by PPIs could result in decreased intestinal calcium absorption. Subsequently, there have been concerns that the chronic use of a PPI is associated with an increased risk of bone fracture. However, the results of clinical studies

2011 EvidenceUpdates

153. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Full Text available with Trip Pro

Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Concerns have been raised about the risk of fractures with acid-suppressive medications, such as proton pump inhibitors and histamine(2)-receptor antagonists.This meta-analysis evaluated the association between proton pump inhibitor or histamine(2)-receptor antagonist use and fractures. We performed a systematic search of published literature (1970 to October 10, 2010) in MEDLINE, EMBASE, and other (...) sources. Ten publications reporting 11 studies were considered eligible for analysis.All studies were observational case-control or cohort studies and primarily evaluated older adults. The summary effect estimate for risk of hip fracture increased modestly among individuals taking proton pump inhibitors (relative risk [RR] 1.30, 95% confidence interval [CI], 1.19-1.43). There also was an increase in spine (RR 1.56, 95% CI, 1.31-1.85) and any-site fractures (RR 1.16, 95% CI, 1.04-1.30) among proton

2011 EvidenceUpdates

154. Proton pump inhibitor use and the antifracture efficacy of alendronate Full Text available with Trip Pro

Proton pump inhibitor use and the antifracture efficacy of alendronate Proton pump inhibitors (PPIs) are widely used in elderly patients and are frequently coadministered in users of oral bisphosphonates. Biologically, PPIs could affect the absorption of calcium, vitamin B(12), and bisphosphonates and could affect the osteoclast proton pump, thus interacting with bisphosphonate antifracture efficacy. Moreover, PPIs themselves have been linked to osteoporotic fractures.Population-based, national

2011 EvidenceUpdates

155. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review (Abstract)

Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review Use of proton-pump inhibitors (PPIs) for the treatment of gastroesophageal reflux disease (GERD) in children has increased enormously. However, effectiveness and safety of PPIs for pediatric GERD are under debate.We performed a systematic review to determine effectiveness and safety of PPIs in children with GERD.We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews

2011 EvidenceUpdates

156. The Efficacy of Proton Pump Inhibitors for the Treatment of Asthma in Adults: A Meta-analysis. Full Text available with Trip Pro

The Efficacy of Proton Pump Inhibitors for the Treatment of Asthma in Adults: A Meta-analysis. Gastroesophageal reflux disease occurs frequently among patients with asthma. Therapy with proton pump inhibitors (PPIs) to improve asthma control remains controversial. We sought to evaluate the efficacy of PPIs in treatment of asthma using objective and subjective outcome measures.A literature search was undertaken using MEDLINE (1950-January 2010), PubMed (1950-January 2010), EMBASE (1980-January (...) with gastroesophageal reflux disease (mean difference, 16.90 L/min [95% confidence interval, 0.85-32.95]). Analyses of secondary outcomes (asthma symptoms score, Asthma Quality of Life Questionnaire score, evening PEF rate, and forced expiratory volume in 1 second) showed no significant difference between PPIs and placebo.Proton pump inhibitor therapy in adults with asthma results in a small, statistically significant improvement in morning PEF rate. The magnitude of this improvement, however, is unlikely

2011 EvidenceUpdates

157. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis

The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

158. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention (Abstract)

Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention The aim of the present study was to analyze the effect of drug exposure patterns of clopidogrel and proton pump inhibitors (PPIs) on the clinical outcomes after percutaneous coronary intervention (PCI). Previous analyses predominantly included discharge medications and did not explore the effect of the drug exposure patterns. We analyzed all-cause death, nonfatal myocardial infarction

2011 EvidenceUpdates

159. Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention Full Text available with Trip Pro

Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention Aspirin reduces myocardial infarction but increases gastrointestinal tract (GI) bleeding. Proton pump inhibitors (PPIs) may reduce upper GI bleeding. We estimate the cost-utility of aspirin treatment with or without a PPI for coronary heart disease (CHD) prevention among men at different risks for CHD and GI bleeding.We updated a Markov model to compare costs and outcomes of low-dose aspirin plus PPI (omeprazole, 20 mg/d

2011 EvidenceUpdates

160. Proton pump inhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection: a meta-analysis of randomized trials

Proton pump inhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection: a meta-analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.